Kristine Mørch's picture

Kristine Mørch

Associate Professor, Head National Center for Tropical Infectious Diseases, Haukeland University Hospital
  • E-mailkristine.morch@uib.no
  • Phone004755975660
  • Visitor Address
    Department of Medicine, Haukeland University Hospital
    5021 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen

Kristine Mørch, MD, PhD, is head of National Center for Tropical Infectious Diseases at Infectious Diseases Section, Department of Medicine, Haukeland university hospital. She is also associate professor at Department of Clinical Science, University of Bergen. Her main research interest is the field of tropical infectious diseases, particularly acute febrile diseases and malaria, as well as giardiasis with focus on resistance and treatment of metronidazol refractory infections. 

Academic article
  • Show author(s) (2023). Clinical features and risk factors for death in acute undifferentiated fever: A prospective observational study in rural community hospitals in six states of India. Transactions of the Royal Society of Tropical Medicine and Hygiene. 91-101.
  • Show author(s) (2022). No difference in serum levels of B-cell activating receptor and antibodies against cytolethal distending toxin B and flagellin in post-infectious irritable bowel syndrome and chronic fatigue syndrome after Giardia infection. Journal of Gastroenterology and Hepatology Open (JGH Open). 185-188.
  • Show author(s) (2022). Malaria prevalence and performance of diagnostic tests among patients hospitalized with acute undifferentiated fever in Zanzibar. Malaria Journal. 1-8.
  • Show author(s) (2021). Schistosomiasis hos norske studenter etter opphold i Afrika. Tidsskrift for Den norske legeforening. 243-247.
  • Show author(s) (2021). Presence of interferon-λ 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus. Scandinavian Journal of Gastroenterology. 849-854.
  • Show author(s) (2021). Leishmaniasis i Norge. Tidsskrift for Den norske legeforening. 1-9.
  • Show author(s) (2021). Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: A TropNet Study. Clinical Infectious Diseases. 1517-1523.
  • Show author(s) (2021). Antibiotics for gastroenteritis in general practice and out-of-hours services in Norway 2006-15. Family Practice. 19-25.
  • Show author(s) (2020). The relation of 25-hydroxy vitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection. PLOS ONE. 1-16.
  • Show author(s) (2020). Giardiasis treatment: an update with a focus on refractory disease. Current Opinion in Infectious Diseases. 355-364.
  • Show author(s) (2020). Detection of remaining Plasmodium DNA and gametocytes during follow up after curative malaria treatment among returned travellers in Norway. Malaria Journal.
  • Show author(s) (2020). Bacteraemia, malaria, and case fatality among children hospitalized with fever in Dar es Salaam, Tanzania. Frontiers in Microbiology. 1-10.
  • Show author(s) (2019). En mann i 80-årene med leddgikt og vedvarende feber. Tidsskrift for Den norske legeforening. 6 pages.
  • Show author(s) (2019). Assessment of malaria real-time PCR methods and application with focus on lowlevel parasitaemia. PLOS ONE. 1-15.
  • Show author(s) (2017). Severe malaria in Europe: an 8-year multi-centre observational study. Malaria Journal. 1-11.
  • Show author(s) (2017). Serovar prevalence of leptospira in semirural India and the development of an igm-based indirect ELISA. Journal of Infection in Developing Countries. 234-241.
  • Show author(s) (2017). Schistosomiasis in european travelers and migrants: Analysis of 14 years tropnet surveillance data. American Journal of Tropical Medicine and Hygiene. 567-574.
  • Show author(s) (2017). Giardia-specific cellular immune responses in post-giardiasis chronic fatigue syndrome. BMC Immunology. 1-8.
  • Show author(s) (2017). Acute undifferentiated fever in India: A multicentre study of aetiology and diagnostic accuracy. BMC Infectious Diseases. 1-11.
  • Show author(s) (2016). Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience. Scandinavian Journal of Gastroenterology. 337-343.
  • Show author(s) (2016). Postinfectious and sporadic functional gastrointestinal disorders have different prevalences and rates of overlap: results from a controlled cohort study 3 years after acute giardiasis. Neurogastroenterology and Motility. 1561-1569.
  • Show author(s) (2016). A high malaria prevalence identified by PCR among patients with acute undifferentiated fever in India. PLOS ONE.
  • Show author(s) (2015). Schistosomiasis in pregnant travelers: A case series. Journal of Travel Medicine (JTM). 94-98.
  • Show author(s) (2015). Intravenous artesunate reduces parasite clearance time, duration of intensive care, and hospital treatment in patients with severe malaria in Europe: The TropNet severe malaria study. Clinical Infectious Diseases. 1441-1444.
  • Show author(s) (2015). Beredskap ved alvorlig malaria. Tidsskrift for Den norske legeforening. 533-535.
  • Show author(s) (2014). Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology. 2131-2139.
  • Show author(s) (2014). Irritable bowel syndrome and chronic fatigue 6 years after Giardia infection: A controlled prospective cohort study. Clinical Infectious Diseases. 1394-1400.
  • Show author(s) (2014). A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. PLOS ONE.
  • Show author(s) (2013). Fever in the tropics: aetiology and case-fatality - a prospective observational study in a tertiary care hospital in South India. BMC Infectious Diseases. 8 pages.
  • Show author(s) (2013). Chronic fatigue syndrome 5 years after giardiasis: differential diagnoses, characteristics and natural course. BMC Gastroenterology. 17 pages.
  • Show author(s) (2013). A novel, single-amplification PCR targeting mitochondrial genome highly sensitive and specific in diagnosing malaria among returned travellers in Bergen, Norway. Malaria Journal. 8 pages.
  • Show author(s) (2012). The impact of atopic disease on the risk of post-infectious fatigue and irritable bowel syndrome 3 years after Giardia infection. A historic cohort study. Scandinavian Journal of Gastroenterology. 956-961.
  • Show author(s) (2012). PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Medical Genetics. 7 pages.
  • Show author(s) (2012). Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study. Gut. 214-219.
  • Show author(s) (2012). Impact of Obesity on the Bioavailability of Peginterferon-alpha 2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3. PLOS ONE. 7 pages.
  • Show author(s) (2012). Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLOS ONE. 7 pages.
  • Show author(s) (2012). Immunophenotyping in post-giardiasis functional gastrointestinal disease and chronic fatigue syndrome. BMC Infectious Diseases. 258.
  • Show author(s) (2012). Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection. European Journal of Clinical Microbiology and Infectious Diseases. 1631-1635.
  • Show author(s) (2011). Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection. Journal of Viral Hepatitis. 245-251.
  • Show author(s) (2011). Intravenous Artesunate for Severe Malaria in Travelers, Europe. Emerging Infectious Diseases. 771-777.
  • Show author(s) (2011). Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. Journal of Infectious Diseases. 1748-1752.
  • Show author(s) (2011). Hepatitis C treatment response kinetics and impact of baseline predictors. Journal of Viral Hepatitis. 1-7.
  • Show author(s) (2010). Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations? Clinical Infectious Diseases. E22-E25.
  • Show author(s) (2010). Giardiasis: the ever-present threat of a neglected disease. Current Drug Targets - Infectious Disorders. 329-348.
  • Show author(s) (2010). Giardiasis ? why do the symptoms sometimes never stop? Trends in Parasitology. 75-82.
  • Show author(s) (2010). Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology. 430-435.
  • Show author(s) (2009). Severity of Giardia infection associated with post-infectious fatigue and abdominal symptoms two years after. BMC Infectious Diseases.
  • Show author(s) (2009). High rate of fatigue and abdominal symptoms 2 years after an outbreak of giardiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene. 530-532.
  • Show author(s) (2008). Treatment-ladder and genetic characterisation of parasites in refractory giardiasis after an outbreak in Norway. Journal of Infection. 268-273.
  • Show author(s) (2008). Sensitivity of a Giardia antigen test in persistent giardiasis following an extensive outbreak. Clinical Microbiology and Infection (CMI). 1069-1071.
  • Show author(s) (2008). Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology. 1837-1835.
  • Show author(s) (2008). Effects of albendazole/metronidazole or tetracycline/folate treatments on persisting symptoms after Giardia infection: A randomized open clinical trial. Scandinavian Journal of Infectious Diseases. 517-522.
  • Show author(s) (2022). Apekopper i Norge. Tidsskrift for Den norske legeforening.
Reader opinion piece
  • Show author(s) (2015). Hund som Giardia-kilde i Bergen i 2004 - barking up the wrong tree? Tidsskrift for Den norske legeforening. 1718-1720.
  • Show author(s) (2011). Early determination of Hepatitis C virus RNA may help to decide the duration of therapy for chronic Hepatitis C virus genotype 2/3 infection. Hepatology. 1067-1068.
  • Show author(s) (2008). Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. Hepatology. 695-695.
Short communication
  • Show author(s) (2015). Severe human Babesia divergens infection in Norway. International Journal of Infectious Diseases. 37-38.
Feature article
  • Show author(s) (2013). Utveksling av helsepersonell mellom Bergen og Zanzibar. Tidsskrift for Den norske legeforening. 187-189.
Doctoral dissertation
  • Show author(s) (2019). PCR based Malaria diagnostics – Method development and application.
  • Show author(s) (2010). Giardiasis - with emphasis on treatment and post-infectious manifestations.
  • Show author(s) (2012). Impact of Inosine Triphosphatase (ITPA) Gene Variants on Anemia, Ribavirin Concentrations, and Outcome During Therapy for HCV Genotype 2/3. Hepatology. 1023A-1023A.
  • Show author(s) (2012). A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. Hepatology. 682A-683A.
  • Show author(s) (2011). Impact of obesity on the bioavailability of peginterferon-alpha 2A and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. Hepatology. 1321A-1322A.
  • Show author(s) (2008). Twelve weeks of treatment is insufficient for HCV genotype 2 and 3 infected patients with steatosis. Journal of Hepatology. S314-S315.
  • Show author(s) (2008). Ribavirin concentration at week four is an independend predictor for sustained virological response after treatment of hepatitis C genotype 2/3 (NORDynamic trial). Journal of Hepatology. S6-S7.
  • Show author(s) (2007). Peginterferon alfa-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2/3: The nordynamic trial. Hepatology. 815A-816A.
  • Show author(s) (2007). Comparison of peginterferon alpha-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2/3: The nordynamic trial. Journal of Hepatology. S229-S229.
  • Show author(s) (2018). Schistosomiasis in Norwegian medical students .
Academic literature review
  • Show author(s) (2010). Giardiasis - why do the symptoms sometimes never stop? Trends in Parasitology. 75-82.

More information in national current research information system (CRIStin)